Routine insider filing for a new C-suite officer — no immediate catalyst. Monitor future Form 4 filings for any open-market purchases or sales by Schecter.
Price Chart
Executive Summary
Alison D. Schecter filed an initial Statement of Beneficial Ownership (Form 3) with the SEC, reporting her appointment as Chief Medical Officer of Retension Pharmaceuticals, Inc. The filing discloses a grant of stock options to purchase 152,980 shares at an exercise price of $2.43 per share, vesting monthly over approximately three years. This is a routine insider filing for a new officer and carries no material price impact.
Key Facts
- Alison D. Schecter appointed as Chief Medical Officer of Retension Pharmaceuticals, Inc.
- Schecter filed Form 3 on October 10, 2026, reporting beneficial ownership.
- Schecter holds a non-derivative stock option to buy 152,980 shares at $2.43 per share.
- Option granted May 1, 2026; vests in 1/36 monthly increments starting March 23, 2026.
- No open-market purchase or sale reported — only a grant of compensatory equity.
Financial Impact
No financial impact — the filing is a routine initial ownership disclosure for a new officer. The option grant is compensatory and not a market transaction.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001213900-26-108139 |
| Document: 0001213900-26-108139-index-headers.html | 0001213900-26-108139 |
| Document: 0001213900-26-108139-index.html | 0001213900-26-108139 |
| Document: 0001213900-26-108139.txt | 0001213900-26-108139 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $15.25 | awaiting T+5 | — | $15.25 (0.00%) |
Oct 16, 2026 10d ago | SC 13G | $16.33 $14.65 | ▼ −10.29% | ▼ −10.14% | $15.25 (−6.61%) |
Oct 16, 2026 10d ago | SC 13G | $14.07 $15.25 | ▲ +8.39% | ▲ +8.82% | $15.25 (+8.39%) |
Oct 15, 2026 11d ago | SC 13G | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $15.25 (+24.90%) |
Oct 14, 2026 12d ago | SC 13D | $12.21 $15.50 | ▲ +26.95% | ▲ +27.96% | $15.25 (+24.90%) |
Oct 13, 2026 13d ago | Insider Cluster | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $15.25 (+31.01%) |
Oct 13, 2026 13d ago | 3 | $11.64 $15.00 | ▲ +28.87% | ▲ +28.41% | $15.25 (+31.01%) |
Oct 9, 2026 17d ago | 424B4 | $11.32 $16.33 | ▲ +44.26% | ▲ +45.75% | $15.25 (+34.72%) |
Oct 9, 2026 17d ago | EFFECT | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $15.25 (+44.82%) |
Oct 8, 2026 18d ago | 3 | $10.53 $14.07 | ▲ +33.62% | ▲ +35.59% | $15.25 (+44.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers